Treatment for lupus nephritis (Q24247408)

1

0 references

Matthew A Roberts

2

0 references

Steven J Chadban

4

0 references

Peter G Kerr

5

0 references

Robert C Atkins

Cochrane Database of Systematic Reviews

6

0 references

publication date

26 January 2004

0 references

published in

0 references

cites work

NIH conference. Systemic lupus erythematosus: evolving concepts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Cyclophosphamide in lupus nephritis: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Prognostic factors in lupus nephritis. Contribution of renal histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Treatment of lupus nephritis: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Clinical trials in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Efficacy of low-dose versus high-dose cyclophosphamide in lupus nephritis: comment on the article by Houssiau et al

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Azathioprine in the treatment of systemic lupus erythematosus. A controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Misoprostol and Prednisone Treatment of Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Management of lupus nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Treatment of Lupus Nephritis with Prednisone and Combined Prednisone and Azathioprine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB2

7 January 2021